Ad-hoc Releases

Fast information flow: We keep you up to date on all company occurrences that could influence the share price significantly.

Key Information

Listed companies are obliged by law to publish without delay news of all company occurrences that could influence the share price significantly (Article 17 of the European Market Abuse Regulation (MAR)). We are committed to transparency and want to ensure that all capital market participants have access to key information about our company as quickly as possible, and thus prevent insider dealing due to any information asymmetry.

investors-shareholders investors-shareholders
Shareholders
Read More
Shareholders
Our investor base is as diverse and international as our company itself. Since our share is a bearer share only, NASDAQ provides an analysis of our top investors as well as our shareholder structure by type and region.
Close up businessman signing documents. Close up businessman signing documents.
Directors' Dealings
Read More
Directors' Dealings
As required by German law, we are transparent about any transactions, above a certain threshold, made by persons discharging managerial responsibilities at Merck KGaA, Darmstadt, Germany.
A closeup of a bronze casting depicting a stylized bull in contrasting light representing a bull financial market on a isolated dark background A closeup of a bronze casting depicting a stylized bull in contrasting light representing a bull financial market on a isolated dark background
Voting Rights Notifications
Read More
Voting Rights Notifications
Investors are required by law to inform Merck KGaA, Darmstadt, Germany, and the responsible German Authorities if certain thresholds concerning their Voting Rights are reached or crossed.

Related News

View All News

  1. Press Releases

    Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive ...

    Merck KGaA, Darmstadt, Germany announced it has strengthened its Oncology franchise by regaining exclusive worldwide rights to anti-programmed death ligand-1 (PD-L1) antibody BAVENCIO®

    2023/03/27